Project Grant 2405853
Award Date 7/15/24
Completion Date 6/30/25
Dollars Obligated $275K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10024, USA
Similar Awards
- This SBIR Phase I project awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program seeks to develop a new class of gene therapies that can be delivered more safely, cost-effectively, and at scale for a wide range of serious genetic disorders. The project leverages short oligonucleotides conjugated with small molecules to induce proximity of endogenous epigenetic machinery to disease-relevant genes in a precise and reversible...
- The U.S. National Science Foundation (NSF) awarded a $303,864 Phase I Small Business Innovation Research (SBIR) grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Core Biotherapeutics, Inc. (UEI N9FGZ15RQGJ4) located in Ladera Ranch, CA. The project aims to develop a platform for discovering therapeutic drug candidates that can modulate molecular networks driving diseases, with the potential to produce disease-modifying effects for neurodegenerative...
- The National Science Foundation (NSF) awarded a $275,000 Project Grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Foragr Medicines, Inc. for a SBIR Phase I project titled "High-Throughput Platform for Small Molecule, In-Cell Targeting of Undruggable Proteins via their mRNAs". The project aims to develop a high-throughput drug discovery platform to identify small molecule drugs that can target the mRNA of hard-to-treat diseases, including...
- This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...
- This Project Grant award from the National Science Foundation (NSF) under its Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Tectaria Bio LLC to engineer cell lines with activated proteasomes for increased biomanufacturing efficiency. The project aims to test the feasibility and application of a novel technology to significantly increase the protein production capabilities of cell lines used in the manufacture of biologics, gene therapies, and vaccines....
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Om Therapeutics Inc. will support the development of a system to enable the rapid, scalable, and cost-effective discovery of new medicines using machine learning. The project aims to encapsulate proteins and small molecules in millions of miniaturized compartments to screen for interactions that could identify novel drug candidates. The key innovations include...
- This $448,150 Project Grant awarded by the National Science Foundation (NSF) Biological Sciences program (CFDA 47.074) aims to develop a DNA-based toolbox for the rapid and precise modulation of cell membrane protein-protein interactions (PPIs). The goal is to establish a modular approach using antibodies and aptamers to enable targeted DNA barcoding of cell membrane proteins, particularly receptor tyrosine kinases. This will allow for the controlled stabilization of specific PPI pairs on living...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 provides funding to Clue Genetics Inc. for the development of a fungi-focused metabologenomics platform for natural product discovery. The key products and services to be delivered under this 1-year Phase I SBIR project include: Annotating biosynthetic gene clusters (BGCs) from 200 genomes selected from a diverse set of bioactive fungi to uncover new drugs,...
- This $274,797 National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Deepseq.ai LLC supports the development of an AI-driven platform to accelerate the identification of highly developable single-domain antibodies for drug discovery. The proposed work aims to create a multimodal AI model capable of rapidly screening large libraries to generate lead molecules with favorable binding affinity, stability, and manufacturability. This project...
- The National Science Foundation (NSF) awarded a $274,640 Project Grant under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) to Protein Design Solutions LLC, a for-profit limited liability company located in Allentown, PA. The grant funding will support the development of a computational platform to predict and mitigate protein aggregation issues in the development of protein-based therapeutics. Specifically, the project aims to leverage state-of-the-art...